New era with target-specific agents for RA

Abstract

Four new immunomodulatory drugs look set to change the way that patients with rheumatoid arthritis (RA) are treated in the next millennium. This is the beginning of an era of rational, target-specific, treatment of RA, delegates were told at the 1998 Annual Meeting of the American College of Rheumatology [San Diego, US; November 1998]. These drugs provide new treatment options for patients with early and late disease and for patients with moderate to severe RA symptoms. There is considerable excitement among rheumatology researchers regarding the potential of these new treatment strategies.